Drug intelligence / Profile preview

Stifen-MR

Development stage
Unknown
Lead developer
Med Manor Organics
Modality
Small Molecules
Administration
Oral
01

Overview

Stifen-MR is a fixed-dose combination tablet developed and marketed by Med Manor Organics for the treatment of acute musculoskeletal pain, muscle spasms, and inflammatory conditions such as arthritic pain, sprains, and strains. It contains three active ingredients: aceclofenac, a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis; paracetamol (acetaminophen), an analgesic and antipyretic that provides additional pain relief; and chlorzoxazone, a centrally acting muscle relaxant that acts on the spinal cord and subcortical areas of the brain to inhibit multi-synaptic reflex arcs. Together, these components work synergistically to alleviate pain, reduce inflammation, and relieve muscle stiffness and spasms, thereby improving physical mobility.

Brand names
Stifen-MR
Other names
Aceclofenac + Chlorzoxazone + ParacetamolAceclofenac + Paracetamol + Chlorzoxazone
02

Targets

KCNMA1 (Calcium-activated potassium channel subfamily M alpha member 1)KCNN4 (Intermediate conductance calcium-activated potassium channel protein 4)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Stifen-MR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stifen-MR.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call